Insulet Co. (PODD) Expected to Post Earnings of $0.03 Per Share

Analysts forecast that Insulet Co. (NASDAQ:PODD) will post earnings of $0.03 per share for the current quarter, Zacks reports. Nine analysts have made estimates for Insulet’s earnings. The highest EPS estimate is $0.09 and the lowest is ($0.02). Insulet reported earnings per share of ($0.03) during the same quarter last year, which suggests a positive year over year growth rate of 200%. The business is scheduled to report its next earnings report on Thursday, August 1st.

On average, analysts expect that Insulet will report full year earnings of $0.26 per share for the current year, with EPS estimates ranging from $0.09 to $0.41. For the next fiscal year, analysts anticipate that the business will report earnings of $0.77 per share, with EPS estimates ranging from $0.44 to $1.44. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Insulet.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.05. The company had revenue of $159.56 million for the quarter, compared to the consensus estimate of $154.66 million. Insulet had a return on equity of 7.25% and a net margin of 2.37%. The firm’s revenue was up 29.1% compared to the same quarter last year. During the same period last year, the business posted ($0.11) earnings per share.

Several brokerages have recently issued reports on PODD. Canaccord Genuity reiterated a “buy” rating and issued a $110.00 target price (up previously from $100.00) on shares of Insulet in a research note on Monday. Oppenheimer set a $100.00 target price on shares of Insulet and gave the company a “hold” rating in a research note on Tuesday, February 26th. BidaskClub upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 19th. Northland Securities reiterated a “buy” rating and issued a $100.00 target price on shares of Insulet in a research note on Tuesday, February 26th. Finally, BTIG Research upgraded shares of Insulet from a “neutral” rating to a “buy” rating and set a $115.00 target price for the company in a research note on Monday. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $105.18.

In other Insulet news, Director David A. Lemoine sold 561 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $94.29, for a total transaction of $52,896.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP David Colleran sold 7,395 shares of the firm’s stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $94.89, for a total transaction of $701,711.55. The disclosure for this sale can be found here. In the last quarter, insiders sold 80,304 shares of company stock valued at $7,589,000. 3.50% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of PODD. Manchester Capital Management LLC bought a new position in shares of Insulet in the first quarter valued at approximately $31,000. PRW Wealth Management LLC bought a new position in shares of Insulet in the fourth quarter valued at approximately $40,000. Quadrant Capital Group LLC raised its stake in shares of Insulet by 1,037.7% in the first quarter. Quadrant Capital Group LLC now owns 603 shares of the medical instruments supplier’s stock valued at $55,000 after acquiring an additional 550 shares during the last quarter. Cutler Group LP bought a new position in shares of Insulet in the fourth quarter valued at approximately $126,000. Finally, US Bancorp DE raised its stake in shares of Insulet by 63.8% in the first quarter. US Bancorp DE now owns 1,405 shares of the medical instruments supplier’s stock valued at $133,000 after acquiring an additional 547 shares during the last quarter.

Shares of NASDAQ:PODD opened at $102.81 on Monday. The stock has a market capitalization of $6.13 billion, a PE ratio of 2,056.20 and a beta of 1.50. Insulet has a 52-week low of $70.80 and a 52-week high of $108.90. The company has a debt-to-equity ratio of 2.79, a quick ratio of 3.37 and a current ratio of 3.99.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Further Reading: Strike Price

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.